MicroRNA 181b regulates decorin production by dermal fibroblasts and may be a potential therapy for hypertrophic scar

50Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

Abstract

Hypertrophic scarring is a frequent fibroproliferative complication following deep dermal burns leading to impaired function and lifelong disfigurement. Decorin reduces fibrosis and induces regeneration in many tissues, and is significantly downregulated in hypertrophic scar and normal deep dermal fibroblasts. It was hypothesized that microRNAs in these fibroblasts downregulate decorin and blocking them would increase decorin and may prevent hypertrophic scarring. Lower decorin levels were found in hypertrophic scar as compared to normal skin, and in deep as compared to superficial dermis. A decorin 3' un-translated region reporter assay demonstrated microRNA decreased decorin in deep dermal fibroblasts, and microRNA screening predicted miR- 24, 181b, 421, 526b, or 543 as candidates. After finding increased levels of mir-181b in deep dermal fibroblasts, it was demonstrated that TGF- β 1 stimulation decreased miR-24 but increased miR-181b and that hypertrophic scar and deep dermis contained increased levels of miR-181b. By blocking miR-181b with an antagomiR, it was possible to increase decorin protein expression in dermal fibroblasts. This suggests miR-181b is involved in the differential expression of decorin in skin and wound healing. Furthermore, blocking miR-181b reversed TGF-β 1 induced decorin downregulation and myofibroblast differentiation in hypertrophic scar fibroblasts, suggesting a potential therapy for hypertrophic scar.

Figures

  • Fig 1. Immunohistochemical DCN expression in HSc and site-matched NS from burn patients. (a) Immunohistochemistry using a polyclonal goat antihuman DCN antibody and Alexa Fluor 488 secondary antibody (green fluorescence), and counterstained with DAPI (blue fluorescence) in representative site-matched sections of NS and HSc (scale bar = 50 μm). (b) Relative expression of DCN in matched superficial and deep NS and HSc sections was calculated from fluorescence using ImageJ (mean ± SEM, n = 4 patients, * P< 0.001).
  • Fig 2. Evidence for the involvement of miRNA inDCN downregulation in DF. Total RNA was extracted from SF and DF cell culture after 48 hours and relative expression of selected miRNA quantitated using RTqPCR (mean ± SEM, n = 3, * P< 0.05).
  • Fig 3. Regulation of miRNA expression by TGF-β1 in SF and DF.Cells were cultured in DMEM + 2% FBS with the indicated treatment protocols and total RNA extracted for RT-qPCR. (a) Dose-response curve showing relative expression of miR-24 for SF and DF cultured in increasing concentrations of TGF-β1 for 48
  • Fig 4. Relative expression of miR-181b in matched superficial and deep dermis and site-matched NS and HSc biopsies. Total RNA was extracted from tissue specimens using a chilled pestle and mortar and Trizol for relative quantitation using RT-qPCR. (a) Relative expression of miR-181b in matched superficial and deep dermis of NS (mean ± SEM, n = 3 samples per patient, * P< 0.001). (b) Relative expression of miR-181b in matched NS and HSc (mean ± SEM, n = 3 samples per patient, * P< 0.05, ** P< 0.01).
  • Fig 5. Regulation of DCN bymiR-181b. HEK293A were cultured in DMEM + 2% FBS and transfected with pmirGLO constructs containing various miRNA binding sites and (a) relative fluorescence quantitated using a luminometer to determine relative knockdown by miR-181b (mean ± SEM, n = 4, *** P 0.01). SF were
  • Fig 6. The effect of antagomiR-181b on TGF-β1 stimulated NS and HSc fibroblasts. (a) antagomiR-181b reversed DCN downregulation in HSc fibroblasts. Cells were stimulated by TGF-β1 at indicated concentrations and transfected with antagomiR-control or antagomiR-181b for 48 hours in DMEM + 2% FBS, and DCN protein was measured using ELISA on the supernatants (mean ± SEM, n = 3, * P< 0.02, ** P< 0.006). (b) antagomiR-181b reversed myofibroblast differentiation in HSc fibroblasts. Cells were stimulated by TGF-β1 10 ng/mL and transfected with antagomiR-control or antagomiR-181b for 48 hours in DMEM + 2% FBS then permeabilized and stained for α-smooth muscle actin and 10 000 cells per sample measured by flow cytometry (mean ± SEM, n = 3, *** P<0.03).

References Powered by Scopus

Analyzing real-time PCR data by the comparative C<inf>T</inf> method

21226Citations
N/AReaders
Get full text

Most mammalian mRNAs are conserved targets of microRNAs

7150Citations
N/AReaders
Get full text

Prediction of Mammalian MicroRNA Targets

4446Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Wound healing

637Citations
N/AReaders
Get full text

Regenerative Scar-Free Skin Wound Healing

189Citations
N/AReaders
Get full text

Current approaches targeting the wound healing phases to attenuate fibrosis and scarring

167Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kwan, P., Ding, J., & Tredget, E. E. (2015). MicroRNA 181b regulates decorin production by dermal fibroblasts and may be a potential therapy for hypertrophic scar. PLoS ONE, 10(4). https://doi.org/10.1371/journal.pone.0123054

Readers over time

‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

59%

Researcher 8

28%

Professor / Associate Prof. 2

7%

Lecturer / Post doc 2

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

44%

Biochemistry, Genetics and Molecular Bi... 11

34%

Agricultural and Biological Sciences 5

16%

Pharmacology, Toxicology and Pharmaceut... 2

6%

Save time finding and organizing research with Mendeley

Sign up for free
0